Posted on April 27th, 2012, 3:56 pm
Medscape April 27, 2012 â Ophthalmologists often use bevacizumab (Avastin, Genentech) off-label to treat wet age-related macular degeneration (AMD) in part because of lower cost compared with on-label use of ranibizumab (Lucentis, Genentech). and more » |